Joel Greenblatt's SUPN Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 7,422 shares of Supernus Pharmaceuticals, Inc. (SUPN) worth $345,197, representing 0.00% of the portfolio. First purchased in 2015-Q1, this long-term strategic position has been held for 36 quarters.
Based on 13F filings, Joel Greenblatt has maintained a strategic position in SUPN, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2017, adding 144,155 shares. Largest reduction occurred in Q1 2018, reducing 106,816 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Supernus Pharmaceuticals (SUPN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Supernus Pharmaceuticals (SUPN) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +7,422 | New Buy | 7,422 | $46.51 |
| Q3 2025 | -17,623 | Sold Out | 0 | $0.00 |
| Q2 2025 | -13,060 | Reduce 42.56% | 17,623 | $31.52 |
| Q1 2025 | -8,529 | Reduce 21.75% | 30,683 | $32.75 |
| Q4 2024 | +1,419 | Add 3.75% | 39,212 | $36.16 |
| Q3 2024 | +26,742 | Add 241.99% | 37,793 | $31.18 |
| Q2 2024 | +4,046 | Add 57.76% | 11,051 | $26.75 |
| Q1 2024 | +7,005 | New Buy | 7,005 | $34.11 |
| Q3 2023 | -8,791 | Sold Out | 0 | $0.00 |
| Q2 2023 | +8,791 | New Buy | 8,791 | $30.06 |
| Q2 2022 | -10,264 | Sold Out | 0 | $0.00 |
| Q1 2022 | -1,010 | Reduce 8.96% | 10,264 | $32.35 |
| Q4 2021 | +1,097 | Add 10.78% | 11,274 | $29.18 |
| Q3 2021 | +10,177 | New Buy | 10,177 | $26.63 |
| Q3 2020 | -10,812 | Sold Out | 0 | $0.00 |
| Q2 2020 | -34,167 | Reduce 75.96% | 10,812 | $23.77 |
| Q1 2020 | -37,468 | Reduce 45.44% | 44,979 | $17.99 |
| Q4 2019 | -21,103 | Reduce 20.38% | 82,447 | $23.72 |
| Q3 2019 | +4,477 | Add 4.52% | 103,550 | $27.48 |
| Q2 2019 | +14,808 | Add 17.57% | 99,073 | $33.09 |
| Q1 2019 | +44,913 | Add 114.13% | 84,265 | $35.04 |
| Q4 2018 | +31,287 | Add 387.94% | 39,352 | $33.21 |
| Q3 2018 | +1,689 | Add 26.49% | 8,065 | $50.34 |
| Q2 2018 | -26,405 | Reduce 80.55% | 6,376 | $59.91 |
| Q1 2018 | -106,816 | Reduce 76.52% | 32,781 | $45.79 |
| Q4 2017 | -28,939 | Reduce 17.17% | 139,597 | $39.85 |
| Q3 2017 | +144,155 | Add 591.26% | 168,536 | $40.00 |
| Q2 2017 | -77,620 | Reduce 76.10% | 24,381 | $43.11 |
| Q1 2017 | +102,001 | New Buy | 102,001 | $31.30 |
| Q3 2016 | -12,455 | Sold Out | 0 | $0.00 |
| Q2 2016 | -5,097 | Reduce 29.04% | 12,455 | $20.39 |
| Q1 2016 | -16,256 | Reduce 48.08% | 17,552 | $15.27 |
| Q4 2015 | -5,334 | Reduce 13.63% | 33,808 | $13.43 |
| Q3 2015 | -49,125 | Reduce 55.66% | 39,142 | $14.03 |
| Q2 2015 | +46,581 | Add 111.74% | 88,267 | $16.98 |
| Q1 2015 | +41,686 | New Buy | 41,686 | $12.09 |
Joel Greenblatt's Supernus Pharmaceuticals Investment FAQs
Joel Greenblatt first purchased Supernus Pharmaceuticals, Inc. (SUPN) in Q1 2015, acquiring 41,686 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Supernus Pharmaceuticals, Inc. (SUPN) for 36 quarters since Q1 2015.
Joel Greenblatt's largest addition to Supernus Pharmaceuticals, Inc. (SUPN) was in Q3 2017, adding 168,536 shares worth $6.74 M.
According to the latest 13F filing for Q2 2026, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 7,422 shares of Supernus Pharmaceuticals, Inc. (SUPN), valued at approximately $345,197.
As of the Q2 2026 filing, Supernus Pharmaceuticals, Inc. (SUPN) represents approximately 0.00% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in Supernus Pharmaceuticals, Inc. (SUPN) was 168,536 shares, as reported at the end of Q3 2017.